Search

Thiamine is a vital co‐factor for several anti‐inflammatory and antioxidant processes that are critical for mitigation of sepsis‐associated inflammation, but pharmacokinetic (PK) analysis has not been reported in horses. We hypothesized that IV thiamine hydrochloride (TH) at increasing dosages would result in corresponding increases in plasma thiamine concentrations without causing adverse effects. A randomized cross‐over study was performed in 9 healthy horses that each received TH at 5, 10, and 20 mg/kg IV. Blood was collected immediately prior to drug administration and at several time points thereafter. High‐performance liquid chromatography with mass spectrometry was used to quantify thiamine concentrations at each time point. Non‐compartmental PK methods showed that IV TH resulted in supraphysiologic plasma concentrations with a short half‐life (0.77–1.12 h) and no adverse clinical signs were observed. The terminal rate constant decreased as the dosage increased (p <.0001) and clearance significantly decreased at the 20 mg/kg dosage (p =.0011). The area under the curve (AUC) increased in a non‐linear fashion. These findings suggest that thiamine follows non‐linear elimination kinetics in horses, which is likely due to saturation of renal elimination. Future studies are needed to identify therapeutic plasma concentrations and develop thiamine dosing recommendations for horses. [ABSTRACT FROM AUTHOR]

Background: In metabolically stable horses, alpha‐2‐agonists suppress insulin secretion with transient hyperglycemia and rebound hyperinsulinemia. In horses with insulin dysregulation (ID), the effect of alpha‐2‐agonists has not been investigated; however, both the alpha‐2‐agonist‐induced suppression of insulin secretion and rebound hyperinsulinemia could have clinical relevance. Hypothesis/Objectives: In horses with ID, alpha‐2‐agonists will alter insulin and glucose dynamics. Animals Seven horses with ID and 7 control horses. Methods: In this randomized crossover study, xylazine hydrochloride (1.1 mg/kg) or detomidine hydrochloride (30 μg/kg) were administered IV, and blood was collected for glucose and insulin concentrations at 0, 15, 30, 45, 60, 90, 120, 150, 180, and 300 minutes after administration. Horses received each drug in a random order with a 24‐hour washout period between drugs. Percent change in glucose and insulin concentrations was compared between groups, drugs, and over time with P <.05 considered significant. Results: A significant time‐dependent effect of both alpha‐2‐agonists on glucose and insulin concentrations in control and ID horses was identified (P =.01 for all comparisons). There was no significant effect of sedative selection and endocrine status on blood glucose concentration in either group; however, in ID horses, xylazine administration resulted in severe rebound hyperinsulinemia whereas detomidine administration did not (P =.02). Conclusions and Clinical Importance: Alpha‐2‐agonists have a significant effect on glucose and insulin concentrations in horses. In ID horses, detomidine could minimize hyperinsulinemia when compared to xylazine. [ABSTRACT FROM AUTHOR]